

K043333

6.0 510(k) Summary

DEC 15 2004

Submitter's Name / Contact Person

Timothy J. Kappers, MBA, RAC
 Manager, Regulatory Affairs
 Vital Images, Inc.
 3300 Fernbrook Lane N, Suite 200
 Plymouth, MN 55447

General Information

Trade Name	Vitrea2, Version 3.7 Medical Image Processing Software
Common / Usual Name	System, Image Processing, Radiological
Classification Name	LLZ, Class II, CFR 21 892.2050
Predicate Devices	<ul style="list-style-type: none"> • Vitrea2, Version 3.5 (K040305) /Version 3.4 (K032748) Vital Images, Inc. • Toshiba Cardiac Functional Analysis (K023760) Toshiba America Medical Systems, Inc. • R2 ImageChecker - LN500 (K023003) R2 Technologies, Inc.

Device Description

The Vitrea2 system is a medical diagnostic device that allows the processing, review, analysis, communication and media interchange of multi-dimensional digital images acquired from a variety of imaging devices. Vitrea2, Version 3.7 is an upgrade to Vitrea2, Version 3.5 (cleared under K040305).

The Vitrea2 system provides multi-dimensional visualization of digital images to aid clinicians in their analysis of anatomy and pathology. The Vitrea2 user interface follows typical clinical workflow patterns to process, review, and analyze digital images, including:

- Retrieve image data over the network via DICOM
- Display images that are automatically adapted to exam type via dedicated protocols
- Select images for closer examination from a gallery of up to six 2D or 3D views

- Interactively manipulate an image in real-time to visualize anatomy and pathology
- Annotate, tag, measure, and record selected views
- Output selected views to standard film or paper printers, or post a report to an Intranet Web server or export views to another DICOM device
- Retrieve reports that are archived on a Web server

Intended Use

Vitrea™ 2 is a medical diagnostic system that allows the processing, review, analysis, communication and media interchange of multi-dimensional digital images acquired from a variety of imaging devices. In addition, the Vitrea2 Version 3.7 has the following additional indications:

CT Colonography The separately-licensed CT Colonography option is intended for closely examining the lumen of the colon using features such as auto-segmentation, axial imaging, multi-planar reformatting, fly-through, simultaneous display of prone and supine images, and transparent wall view.

CT Cardiac The separately-licensed CT Cardiac option contains two components: Coronary Artery Analysis and Cardiac Functional Analysis. The Vital Images' CT Cardiac option provides a variety of tools and views for working with clinical CT images of the coronary arteries, heart, and surrounding tissue.

Coronary Artery Analysis

The Coronary Artery Analysis component of the Vitrea CT Cardiac option is intended for determining the presence and extent of coronary obstructive disease by providing a non-invasive approach to survey a patient's coronary arteries. The vessel probe technology integrated into the CT Cardiac option allows physicians' to click on an artery to simultaneously view the following: the highlighted vessel in 3D, two curved vessel views orthogonal to each other, and cross-sectional views.

Cardiac Functional Analysis

The Cardiac Functional Analysis (CFA) component of the Vitrea CT Cardiac option is intended to be used with CT studies of the heart to assist cardiologists and radiologists in assessing function when producing a cardiac evaluation. The CFA component of the CT Cardiac option includes semi-automatic heart and left ventricle segmentation, including identification of long axis and mitral valve boundaries across multiple phases; calculation of global metrics, including end diastolic volume, end systolic volume, stroke volume, ejection fraction, cardiac output, cardiac index, stroke index, and myocardial mass; and calculation of regional metrics; including wall motion, percentage of wall thickening, regional ejection fraction, and polar plots.

Lung Analysis The separately-licensed Lung Analysis option is intended for the review and analysis of thoracic CT images for the purposes of characterizing nodules in the lung in a

single study, or over the time course of several thoracic studies. Characterizations include diameter, volume and volume over time. The system automatically performs the measurements, allowing lung nodules and measurements to be displayed.

Predicate Device Comparison

The Vitrea2, Version 3.7 system and its predicate devices allow for the analysis, communication and media interchange of digital images acquired from a variety of acquisition devices. All devices support the DICOM protocol for communication of images with other medical imaging devices.

Summary of Studies

The software utilized was designed, developed, tested, and validated according to written procedures. These procedures specify individuals within the organization responsible for developing and approving product specifications, coding, testing, validating and maintenance.

The Vitrea2, Version 3.7 system will successfully complete integration testing/verification testing prior to Beta validation. Software Beta testing/validation will be successfully completed prior to release. In addition, potential hazards have been studied and controlled by a Risk Management Plan.

Conclusion

The Vitrea2, Version 3.7 system has similar intended uses as the predicate devices and has very similar technological characteristics. Minor technological differences do not raise any new questions regarding safety or effectiveness of the device. Thus, the Vitrea2, Version 3.7 system is substantially equivalent to the predicate devices.



Food and Drug Administration
9200 Corporate Boulevard
Rockville MD 20850

DEC 15 2004

Vital Images, Inc.
% Mr. Mark Job
Responsible Third Party Official
Regulatory Technology Services LLC
1394 25th Street NW
BUFFALO MN 55313

Re: K043333
Trade/Device Name: Vitrea™2, Version 3.7 Medical
Image Processing Software
Regulation Number: 21 CFR 892.2050
Regulation Name: Picture archiving and
communications system
Regulatory Class: II
Product Code: 90 LLZ
Dated: November 29, 2004
Received: December 3, 2004

Dear Mr. Job:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (Premarket Approval), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Office of Compliance at one of the following numbers, based on the regulation number at the top of this letter:

21 CFR 876.xxxx	(Gastroenterology/Renal/Urology)	240-276-0115
21 CFR 884.xxxx	(Obstetrics/Gynecology)	240-276-0115
21 CFR 892.xxxx	(Radiology)	240-276-0120
Other		240-276-0100

Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR 807.97). You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address <http://www.fda.gov/cdrh/dsma/dsmamain.html>

Sincerely yours,



Nancy C. Brogdon
Director, Division of Reproductive,
Abdominal, and Radiological Devices
Office of Device Evaluation
Center for Devices and Radiological Health

Enclosure

3.0 Intended Use Statement

510(k) Number (if known): K04 3333

Device Name: **Vitrea™2, Version 3.7 Medical Image Processing Software**

Vitrea™ 2 is a medical diagnostic system that allows the processing, review, analysis, communication and media interchange of multi-dimensional digital images acquired from a variety of imaging devices. In addition, the Vitrea2 Version 3.7 has the following additional indications:

CT Colonography The separately-licensed CT Colonography option is intended for closely examining the lumen of the colon using features such as auto-segmentation, axial imaging, multi-planar reformatting, fly-through, simultaneous display of prone and supine images, and transparent wall view.

CT Cardiac The separately-licensed CT Cardiac option contains two components: Coronary Artery Analysis and Cardiac Functional Analysis. The Vital Images' CT Cardiac option provides a variety of tools and views for working with clinical CT images of the coronary arteries, heart, and surrounding tissue.

Coronary Artery Analysis

The Coronary Artery Analysis component of the Vitrea CT Cardiac option is intended for determining the presence and extent of coronary obstructive disease by providing a non-invasive approach to survey a patient's coronary arteries. The vessel probe technology integrated into the CT Cardiac option allows physicians' to click on an artery to simultaneously view the following: the highlighted vessel in 3D, two curved vessel views orthogonal to each other, and cross-sectional views.

Cardiac Functional Analysis

The Cardiac Functional Analysis (CFA) component of the Vitrea CT Cardiac option is intended to be used with CT studies of the heart to assist cardiologists and radiologists in assessing function when producing a cardiac evaluation. The CFA component of the CT Cardiac option includes semi-automatic heart and left ventricle segmentation, including identification of long axis and mitral valve boundaries across multiple phases; calculation of global metrics, including end diastolic volume, end systolic volume, stroke volume, ejection fraction, cardiac output, cardiac index, stroke index, and myocardial mass; and calculation of regional metrics; including wall motion, percentage of wall thickening, regional ejection fraction, and polar plots.

Lung Analysis The separately-licensed Lung Analysis option is intended for the review and analysis of thoracic CT images for the purposes of characterizing nodules in the lung in a single study, or over the time course of several thoracic studies. Characterizations include diameter, volume and volume over time. The system automatically performs the measurements, allowing lung nodules and measurements to be displayed.

Prescription Use (Part 21 CFR 801 Subpart D)

AND/OR

Over-The-Counter Use _____
(21 CFR 801 Subpart C)

(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE OF NEEDED)

Concurrence of CDRH, Office of Device Evaluation (ODE)

David G. Lyman

(Division Sign-Off)
Division of Reproductive, Abdominal,
and Radiological Devices
510(k) Number K043333

Page ___ of ___